Lactoferrin

Cures Within Reach (CWR) extends partnership with Open Philanthropy to fund 16 clinical trials in low and lower-middle income countries over two years, focusing on affordable treatments using existing medicines, nutraceuticals, and indigenous remedies. The initiative aims to benefit patients in these regions and strengthen local healthcare infrastructure. CWR has already funded successful trials, including a Phase 1 trial in Kenya for snakebite treatment, leading to a $5.4 million grant for a Phase 2B trial in Brazil and Ghana. Future trials will prioritize community engagement and local partnerships.

Witsbb launches Elderberry Yeast β-glucan drink, an immune-boosting product for children aged 6 months to 12 years, adhering to an 'allergy-free' formula and featuring a multi-layered immune nutrient blend, receiving positive market feedback.

MAD Foods plans to launch lactoferrin-enhanced coffee in mid-2024, listing benefits like immune support on cans. TurtleTree's vegan-certified lactoferrin, produced via precision fermentation, will be used. The R&D aims to determine the optimal lactoferrin dose without altering flavor or texture, with prices expected to remain close to SGD$4 per can.